AI Technology Solutions Inc. provides specialized machine learning platforms designed to accelerate data-driven decision-making across healthcare and financial services industries.
AITX demonstrates robust revenue expansion with 277% year-over-year growth in the latest period, suggesting strong product-market fit and scalability; The company is aggressively funding R&D of $3.5M to maintain a technological edge before profitability can be achieved; Strategic partnerships in regulated sectors like healthcare may provide long-term moats once cash flow turns positive.
The company is burning through cash at an annual rate of $12.2M from operations with no clear path to immediate profitability given the negative net income trend; The balance sheet is fragile with current liabilities of $7.6M against only $5.0M in current assets, increasing the risk of default or dilutive capital raises; Persistent losses and a massive deficit in retained earnings suggest fundamental business model issues that equity financing cannot permanently solve.
AITX develops AI-driven software solutions primarily for healthcare, life sciences, and fintech markets. The company leverages machine learning algorithms to optimize data analytics and operational efficiency for enterprise clients. With recent revenue growth outpacing losses, AITX is positioning itself as a high-risk, high-reward player in the expanding artificial intelligence sector.
While revenue surged to $6.1M in 2025, representing a strong growth trajectory, the company continues to report net losses of $-18.9M due to elevated general and administrative expenses of $13.6M. The balance sheet shows a negative shareholders' equity of $-49.9M and total liabilities exceeding assets at $60.5M against $11.0M, highlighting severe solvency concerns despite the cash inflow from share issuances.
The global artificial intelligence market is experiencing rapid expansion driven by demand for automation in complex sectors like healthcare and finance. Companies in this space face high barriers to entry regarding talent and data but offer substantial long-term valuation multiples upon achieving unit economics. Regulatory scrutiny is increasing, particularly for applications involving patient data and credit decisions, which impacts growth strategies.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $1.3M | $2.2M | $6.1M |
| Cost of Revenue | $678.1K | $1.1M | $2.4M |
| Gross Profit | $653.9K | $1.1M | $3.7M |
| Operating Expenses | $13.3M | $15.1M | $17.7M |
| Operating Income | $-12.7M | $-14.0M | $-13.9M |
| R&D | $3.6M | $2.9M | $3.5M |
| G&A | $9.0M | $10.5M | $13.6M |
| Stock-Based Comp | $740.0K | $1.8M | $1.8M |
| D&A | $478.1K | $854.0K | $1.5M |
| Depreciation | $478.1K | $854.0K | $429.1K |
| Other OpEx | $738.4K | $1.7M | $669.9K |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $5.4M | $6.8M | — |
| Pre-Tax Income | $-12.7M | $-14.0M | $-13.9M |
| Income Tax | $5.4M | $6.7M | $5.0M |
| Continuing Ops | $-18.1M | $-20.7M | $-18.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-18.1M | $-20.7M | $-18.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-18.1M | $-20.7M | $-18.9M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $3.4M | $3.6M | $5.0M |
| Accounts Receivable | $265.0K | $756.1K | $1.4M |
| Inventory | $1.6M | $2.1M | $1.6M |
| Other Current Assets | $1.5M | $728.9K | $2.1M |
| Long-Term Assets | $2.9M | $4.0M | $6.0M |
| PP&E (Net) | $315.9K | $268.1K | $258.3K |
| Operating Leases | $1.2M | $1.1M | $1.0M |
| Other LT Assets | $1.3M | $2.6M | $4.7M |
| Total Assets | $6.3M | $7.6M | $11.0M |
| Current Liabilities | $16.0M | $21.7M | $7.6M |
| Current Debt | — | $13.9M | $519.1K |
| Current Leases | $248.7K | $237.7K | $197.3K |
| Deferred Revenue | $9.9K | $73.7K | $91.6K |
| Taxes Payable | $2.8M | — | — |
| Other Current Liab | $13.0M | $7.5M | $6.8M |
| Long-Term Liabilities | $22.1M | $26.1M | $52.9M |
| LT Operating Leases | $950.5K | $889.4K | $810.5K |
| Other LT Liab | $21.1M | $25.2M | $52.1M |
| Total Liabilities | $38.1M | $47.8M | $60.5M |
| Shareholders' Equity | $-31.8M | $-40.2M | $-49.9M |
| Paid-In Capital | $80.2M | $92.6M | $106.3M |
| Retained Earnings | $-112.3M | $-133.0M | $-156.5M |
| Total L&E | $6.3M | $7.6M | $11.0M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-18.1M | $-20.7M | $-18.9M |
| Non-Cash Adjustments | $2.6M | $7.4M | $-163.7K |
| Working Capital Changes | $2.9M | $330.4K | $6.9M |
| Cash from Operations | $-12.6M | $-13.0M | $-12.2M |
| Capital Expenditures | — | $22.2K | $23.7K |
| Cash from Investing | $-308.4K | $4.2K | $-80.0K |
| Cash from Financing | $9.2M | $12.1M | $13.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-3.7M | $-833.8K | $760.0K |
| Beginning Cash | $4.6M | $939.8K | $105.9K |
| Ending Cash | $939.8K | $105.9K | $866.0K |
Healthcare Analytics: Custom AI models for clinical data processing and patient outcome prediction; Life Sciences Research: Algorithms for drug discovery acceleration and genomic data analysis; Fintech Solutions: Predictive fraud detection and automated credit scoring systems; Professional Services: Tailored implementation and ongoing optimization contracts for enterprise clients.
Significant accumulated net losses and a substantial retained earnings deficit indicating persistent operational challenges; Heavy reliance on equity financing evidenced by massive cash flow from financing activities rather than organic profitability; High current liabilities relative to current assets creating immediate liquidity pressure; Intense competition in the AI sector threatening market share and pricing power.
Proprietary algorithms that significantly outperform standard industry models in speed and accuracy; A deep, specialized talent pool of AI researchers with niche expertise in regulated industries; Strong recurring revenue potential from multi-year software licensing and maintenance agreements.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.